Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $120 million, and $250 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”). In addition, Repligen has granted the underwriters of the offering of Shares (the “Shares Offering”) a 30-day option to purchase up to an additional 207,000 Shares and the underwriters of the offering of Notes (the “Notes Offering”) a 13-day option to purchase up to $37.5 million aggregate principal amount of additional Notes solely to cover over-allotments. The sale of the Shares to the underwriters in the Shares Offering is expected to settle on July 19, 2019, subject to
external link icon
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The company recently entered the single-use mixing market with the launch of its MixOne platform, leveraging the success of its existing stainless steel (repeat-use) product line.
external link icon
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results
Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing
Adds a market leader in protein concentration measurement with proprietary and differentiated spectroscopy technology Complements and advances our systems strategy in Chromatography and Filtration C Technologies is expected to contribute approximately $16-$17 million in revenue and be accretive to Repligen’s adjusted earnings per share in 2019 Repligen reports preliminary first quarter 2019 financial results, highlighted by 35%-37% year-over-year organic growth WALTHAM, Mass., April 26, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock. C Technologies
external link icon
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen’s most recent investor presentation will be accessible through the Investor Events section of Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
event icon
Antibody–Drug Conjugate Manufacturing: Driving Process Productivity and Reducing Risk
In this webinar, Field Applications Scientists Zoltán Gulyás and Nigel Herbert discuss how innovative technologies can help ADC manufacturers overcome common process hurdles. Through three real-world case studies, you’ll learn how to: Accelerate processing time and minimize risk to product and operators during tangential flow filtration (TFF) Maintain product consistency and operator safety while minimizing extractables and leachables. Drive process efficiency and reduce turnaround time with accurate, real-time DAR measurement
external link icon
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technologies Closes follow-on equity and convertible debt offerings for net proceeds of $599 million WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2019. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are very pleased with the company’s performance during the second quarter, which included record revenue and 46%
external link icon
Repligen to Present at the 25th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3 at 9:50 a.m. EST. The conference will be held December 3-4, 2013 at the New York Palace Hotel in New York. A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company's website at www.repligen.com ; see News & Events, Events & Presentations. This webcast will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies
external link icon
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it has commenced an underwritten public offering of $100,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation.
Repligen Corporation expects to use the net proceeds of the offering for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the
external link icon
Repligen to Present at Jefferies 2015 Healthcare Conference
WALTHAM, Mass., May 26, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced its upcoming presentation at the Jefferies 2015 Healthcare Conference to be held June 1-4, 2015  at the Grand Hyatt in New York. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, June 3, at 8:00 a.m. EDT.  A live audio webcast of this discussion will be accessible through the Investor Events section of the Company’s website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of
publications icon
Continuous Manufacturing: A Changing Processing Paradigm Publication
Although continuous manufacturing is well established for bulk chemicals, complex automation and validation challenges limit continuous applications for biologics manufacturing. While only a few approved biologic products in the market-less than 10%, according to estimates by Eric Langer, managing partner, BioPlan Associates-are manufactured through perfusion or continuous downstream processing, the field is evolving (1). Most of these processes are done piecewise, however, and are not truly continuous. 
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support